-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Antares Pharma announced that the U.
The ATRS-1902 development program supports the use of Vai's novel proprietary auto-injector platform to deliver a liquid-stable formulation of hydrocortisone for the proposed indication: treatment of acute adrenal insufficiency (known as adrenal crisis) in adults and adolescents
Adrenal crisis, also known as acute adrenal insufficiency, is a clinical syndrome caused by acute failure of adrenal cortex function due to absolute or relative insufficient secretion of adrenal cortical hormones under the action of various reasons
Just recently, Antares Pharma announced positive results from a phase I crossover study of ATRS-1902, which met its primary endpoint: In 32 healthy adults, ATRS-1902 (100 mg) provided a synergistic effect with reference drug Solu Cortef® ( 100 mg) comparable pharmacokinetic profile